The report on Pfizer was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.
Pfizer
BullishExecutive Summary
Investors may question how effectively Pfizer can navigate the challenges posed by rising inflation and interest rates while maintaining its growth trajectory in the biopharmaceutical sector. The company's recent commitment to integrating artificial intelligence into cancer care and the significant increase in holdings by BOCHK Asset Management could strengthen the case for its future performance. However, the current macroeconomic environment presents substantial risks, particularly as inflation in the United States stands at 3.3 percent year over year, potentially dampening consumer demand for pharmaceuticals.
Pfizer's financial health is under scrutiny, with a reported revenue decline from $63.63 billion to $62.58 billion for fiscal year 2025, alongside a drop in EBITDA from $18.13 billion to $15.10 billion. These figures raise concerns about the company's ability to sustain profitability amidst rising operational costs. While the integration of innovative technologies and a flexible workforce may enhance efficiency, investors should remain cautious about the implications of economic pressures on Pfizer's market position and financial stability. The substantial investment by BOCHK Asset Management may indicate positive sentiment, but it is essential to monitor how these developments unfold in the coming quarters.
Next reported earnings: Tuesday, 5 May 2026, before market open.
Key Metrics
| Market Cap | $153.02 B | |
| 6-Month Share Price Change | 8.64% | |
| Revenue (TTM) | $62.58 B | |
| EBITDA (TTM) | $15.10 B | |
| EPS (TTM) | $1.37 | |
| Operating Cash Flow (TTM) | $11.70 B | |
| Free Cash Flow (TTM) | $9.08 B | |
| Cash and cash equivalents | $1.14 B | |
| P/E Ratio (TTM) | 19.68 | |
| Price/Book (TTM) | 1.77 | |
| Debt/Equity | 0.78 | |
| Current Ratio | 1.16 | |
| Dividend Yield (TTM) | 6.39% |
Tap or click the i icon for a metric definition.
The Pfizer Story
Founded in 1849 and headquartered in New York City, Pfizer has evolved into one of the world's leading biopharmaceutical companies. Initially focused on fine chemicals, Pfizer shifted its emphasis to pharmaceuticals in the early 20th century, marking a pivotal moment in its growth trajectory. The company gained prominence with the introduction of penicillin during World War II, establishing its reputation for innovation.
Over the decades, Pfizer has expanded its portfolio through strategic acquisitions, including the purchase of Warner-Lambert in 2000, which brought the blockbuster drug Lipitor into its fold. This cholesterol-lowering medication became one of the best-selling drugs of all time, significantly boosting Pfizer's revenue. In recent years, the company has pivoted towards biotechnology and vaccines, highlighted by its rapid development of a COVID-19 vaccine in collaboration with BioNTech. This achievement not only underscored Pfizer's research capabilities but also positioned it as a key player in global health.
Today, Pfizer's business model centers on research and development, focusing on areas such as oncology, immunology, and rare diseases. The company's commitment to innovation continues to drive its growth, as it seeks to address unmet medical needs while navigating the complexities of the pharmaceutical landscape.
Macro Industry Position
Profitability in the Drug Manufacturers - General industry hinges on effective management of payer and reimbursement pressures, alongside controlling employment costs. Companies in this sector must also navigate the cost of capital for research and development, which significantly impacts their margins. Major players include Johnson & Johnson, Merck & Co., and AbbVie, each leveraging their extensive portfolios to maintain competitive advantages. These firms are well-positioned to respond to evolving market demands while managing the complexities of regulatory environments.
Pfizer's distribution strategy focuses on a broad range of pharmaceutical products, including vaccines and biologics, which have gained prominence in recent years. The company competes with specialized rivals such as Moderna and Gilead Sciences, both of which have carved out niches in the biotechnology and vaccine markets. Pfizer's extensive pipeline and established market presence allow it to adapt swiftly to changing healthcare needs, ensuring a steady flow of innovative treatments to patients.
The current macroeconomic environment presents challenges for the Drug Manufacturers - General industry, particularly regarding inflation and interest rates. Rising consumer prices in the United States may influence demand for pharmaceuticals, while steady policy rates provide a stable backdrop for financing. Additionally, long-term government bond yields remain little changed, affecting the cost of capital for research initiatives. As demographic demand continues to grow, companies like Pfizer must carefully assess these macro factors to sustain their growth trajectories.
Pfizer's ability to deliver value to end customers is increasingly challenged by rising inflation, which stands at 3.3 % year over year in the United States. This inflation impacts household budgets, potentially leading to reduced spending on pharmaceuticals. Meanwhile, the Fed-funds rate remains steady at 3.64 %, providing a stable financing environment for companies like Pfizer. US inflation pressures are compounded by Euro-area inflation at 1.9 % year over year, which could influence cross-border pricing strategies. Additionally, the US 10-year yield is unchanged at 4.29 %, affecting the cost of capital for research and development initiatives, while the UK inflation rate is at 3.4 % and the ECB deposit rate holds at 2.00 %.
Bottom line: Pfizer operates in a complex macroeconomic environment where inflation and interest rates directly influence consumer demand and financing costs. The company's strong market presence and diverse product pipeline position it well to navigate these challenges, but it must remain vigilant about the impact of economic pressures on both reimbursement dynamics and operational costs.
Recent Developments
On April 6, 2026, Pfizer announced its commitment to integrating artificial intelligence into cancer care, highlighting its potential to enhance treatment outcomes and patient management.[1] The company emphasized that AI technologies could streamline processes and improve the efficiency of cancer treatment protocols, although specific details on implementation were not disclosed.[1] This initiative aligns with broader trends in healthcare where AI is increasingly utilized to support clinical decision-making and patient care.[1]
On April 7, 2026, Pfizer transitioned employees from its South San Francisco office to remote roles, citing the space as "underutilized."[2] The decision reflected a shift in workplace strategy, likely influenced by the ongoing changes in work environments post-pandemic. Pfizer did not provide details on how many employees were affected or the future of the office space.[2] This move may indicate a broader trend within the company to adapt to new working conditions and optimize operational costs.[2]
On April 10, 2026, BOCHK Asset Management Ltd reported a significant increase in its holdings of Pfizer shares, acquiring an additional 37,900 shares, which raised its ownership by 2,915.4% during the quarter.[3] Following this acquisition, BOCHK owned a total of 39,200 shares of Pfizer.[3] This substantial increase in investment may reflect confidence in Pfizer's future performance and potential growth in the biopharmaceutical sector.[3]
For investors, these updates suggest a strategic pivot by Pfizer towards innovative technologies and a more flexible workforce, which could enhance operational efficiency and adaptability. The significant investment by BOCHK Asset Management may also indicate positive sentiment regarding Pfizer's stock performance. Investors should monitor these developments closely, as they could impact Pfizer's market position and financial health in the coming quarters. [1]
Sources
- [1] How AI Is Already Reshaping Cancer Care - Pfizer (Apr 6, 2026)
- [2] Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles - Fierce Pharma (Apr 8, 2026)
- [3] BOCHK Asset Management Ltd Acquires 37,900 Shares of Pfizer Inc. $PFE (Apr 10, 2026)
Financial Deep-Dive
Welcome to the Financial Deep-Dive. The eight tabs below organise Pfizer's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Pfizer's financial condition based on their most recent accounts.
Financial Health Summary
For fiscal year 2025, Pfizer reported revenue of $62.58 billion, a decline from $63.63 billion in the previous year. EBITDA also fell, dropping to $15.10 billion from $18.13 billion year over year. In the latest quarter, Pfizer generated revenue of $17.56 billion and EBITDA of $0.76 billion, while operating cash flow for the trailing twelve months stood at $11.71 billion.
Pfizer's market capitalization is currently $153.02 billion, with a price-to-earnings ratio of 19.68 and a price-to-sales ratio of 2.45. These multiples suggest a moderate valuation compared to industry peers. However, the company faces challenges with profitability, as evidenced by a declining net profit margin and return on equity, which fell to 12.4% and 11.6%, respectively. Liquidity appears constrained, with cash and cash equivalents totaling $1.14 billion, while the quick ratio of 0.87 and cash ratio of 0.03 indicate potential difficulties in meeting short-term obligations.
Primary risks for Pfizer include a decline in operating cash flow per share, which has decreased over the reporting period, signaling pressure on cash generation. Additionally, the cash conversion cycle has lengthened, indicating that more days are tied up in working capital, which can hinder operational efficiency. Days of inventory outstanding have also increased, raising concerns about inventory management, while days of payables outstanding have risen, suggesting that suppliers are being paid more slowly, which could impact supplier relationships.
Verdict: Pfizer's financial health shows signs of strain, particularly in cash generation and operational efficiency. The company must address these challenges to stabilize its financial position and restore investor confidence.
Risks and Concerns
Pfizer faces significant operational risks as it navigates a complex macroeconomic landscape marked by rising inflation, currently at 3.3 percent year over year in the United States. This inflationary pressure may dampen consumer spending on pharmaceuticals, potentially impacting demand for Pfizer's products. Additionally, the steady Fed-funds rate of 3.64 percent provides a stable financing environment, but it also underscores the importance of managing costs effectively to maintain profitability.
Financially, Pfizer's recent performance raises red flags for investors. The company reported a revenue decline from $63.63 billion in the previous year to $62.58 billion for fiscal year 2025. EBITDA also fell sharply, from $18.13 billion to $15.10 billion year over year. These figures indicate a troubling trend in cash generation, with operating cash flow for the trailing twelve months at $11.71 billion, suggesting that the company is under pressure to sustain its financial health.
Shareholders should be particularly concerned about the declining net profit margin and return on equity, which have dropped to 12.4 percent and 11.6 percent, respectively. The cash conversion cycle has lengthened, indicating inefficiencies in working capital management. With liquidity constrained—cash and cash equivalents stand at just $1.14 billion—Pfizer must address these financial challenges to restore investor confidence and ensure long-term growth in a competitive biopharmaceutical sector.
Outlook
Pfizer's ability to sustain growth amid rising inflation and interest rates will be critical in the coming quarters. The company's recent commitment to integrating artificial intelligence into cancer care could enhance treatment outcomes and operational efficiency, positioning Pfizer to better navigate economic pressures. However, the impact of inflation on consumer spending may still pose challenges, potentially affecting demand for its pharmaceutical products.
Additionally, the substantial increase in holdings by BOCHK Asset Management signals growing confidence in Pfizer's future performance. This investment reflects a belief in the company's strategic direction and its capacity to adapt to market dynamics. Investors should keep a close eye on how Pfizer manages its operational costs and responds to macroeconomic factors, as these elements will play a significant role in shaping its financial health and market position in the near future.
Red & Green Flags
This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place.
Green Flags
- Pfizer has a strong market capitalization of $153.02 billion.
- The price-to-earnings ratio stands at 19.68, indicating a moderate valuation.
- Earnings per share (EPS) is reported at $1.37.
- Revenue per share has increased over the period.
- Operating cash flow per share has increased over the period.
- Free cash flow per share has increased over the period.
- Return on equity (ROE) has increased over the period.
- Gross profit margin has increased over the period.
- Return on assets (ROA) has increased over the period.
- Return on capital employed (ROCE) has increased over the period.
- Income quality has increased over the period.
- Return on tangible assets has increased over the period.
- The cash conversion cycle has decreased over the period.
- Days of sales outstanding have decreased over the period.
- Days of inventory outstanding have decreased over the period.
- The substantial increase in holdings by BOCHK Asset Management reflects confidence in Pfizer's future performance.
Red Flags
- Revenue declined from $63.63 billion to $62.58 billion year over year.
- EBITDA fell from $18.13 billion to $15.10 billion year over year.
- Net profit margin has decreased over the period.
- Operating profit margin has decreased over the period.
- Pretax profit margin has decreased over the period.
- Cash and cash equivalents are constrained at $1.14 billion.
- The quick ratio is at 0.87, indicating potential difficulties in meeting short-term obligations.
- The cash ratio is at 0.03, suggesting liquidity issues.
- The cash conversion cycle has lengthened, indicating inefficiencies in working capital management.
- Days of payables outstanding have risen, suggesting slower payments to suppliers.
Unknowns
- Details on the implementation of AI technologies in cancer care were not disclosed.
- The number of employees affected by the transition to remote roles is unknown.
- The future of the South San Francisco office space remains unclear.
16 green flags, 10 red flags, 3 unknowns.
Overall View: Bullish.
Action Checklist
Below are the next research steps a retail investor should consider based on this report.
Disclaimer
This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.